Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders amounted to $18.4 million in Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders peaked at $224.1 million during Q3 2022, and registered a low of -$49.5 million during Q1 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$8.9 million (2024), whereas its average is -$5.3 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders surged by 833.67% in 2022, and later crashed by 155.63% in 2023.
  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders (Quarterly) stood at -$44.1 million in 2021, then spiked by 300.84% to $88.5 million in 2022, then slumped by 155.63% to -$49.2 million in 2023, then skyrocketed by 81.95% to -$8.9 million in 2024, then soared by 245.24% to $18.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.